Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen type XIII alpha 1 chain is a transmembranous, nonfibrillar collagen encoded by the COL13A1 gene in humans. Unlike most collagens, which are secreted into the extracellular matrix, collagen XIII embeds in the plasma membrane due to its transmembrane domain. Its function involves cell adhesion—both to the matrix and between cells—playing key roles in development, synaptic organization at neuromuscular junctions, and tissue integrity. It binds heparin, fibronectin, integrins (notably alpha 1), nidogen-2, and perlecan; it can be cleaved to release a soluble extracellular domain. Pathogenic variants cause congenital myasthenic syndromes by impairing neuromuscular junction function. The protein is broadly expressed in connective tissue-producing cells, muscle, placenta, and other tissues; alternative splicing yields multiple isoforms, some with tissue-specific roles.
No direct drugs or inhibitors are known; mechanism of action for potential therapeutic interventions would focus on altering cell-matrix adhesion, receptor clustering, or modulating interactions with integrins and extracellular matrix components
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen type XIII alpha 1 chain (COL13A1).